734 related articles for article (PubMed ID: 19060337)
21. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.
Xiao Z; Chen Z; Gunasekera AH; Sowin TJ; Rosenberg SH; Fesik S; Zhang H
J Biol Chem; 2003 Jun; 278(24):21767-73. PubMed ID: 12676925
[TBL] [Abstract][Full Text] [Related]
22. Differential roles of ATR and ATM in p53, Chk1, and histone H2AX phosphorylation in response to hyperoxia: ATR-dependent ATM activation.
Kulkarni A; Das KC
Am J Physiol Lung Cell Mol Physiol; 2008 May; 294(5):L998-L1006. PubMed ID: 18344416
[TBL] [Abstract][Full Text] [Related]
23. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
Lu X; Nannenga B; Donehower LA
Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R
J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574
[TBL] [Abstract][Full Text] [Related]
25. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
26. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Levesque AA; Fanous AA; Poh A; Eastman A
Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511
[TBL] [Abstract][Full Text] [Related]
27. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling.
Jurvansuu J; Fragkos M; Ingemarsdotter C; Beard P
J Mol Biol; 2007 Sep; 372(2):397-406. PubMed ID: 17663993
[TBL] [Abstract][Full Text] [Related]
28. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.
Iguchi T; Miyakawa Y; Saito K; Nakabayashi C; Nakanishi M; Saya H; Ikeda Y; Kizaki M
Int J Oncol; 2007 Aug; 31(2):285-91. PubMed ID: 17611684
[TBL] [Abstract][Full Text] [Related]
29. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
[TBL] [Abstract][Full Text] [Related]
30. The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints.
Neumann J; Boerries M; Köhler R; Giaisi M; Krammer PH; Busch H; Li-Weber M
Int J Cancer; 2014 Apr; 134(8):1991-2002. PubMed ID: 24150948
[TBL] [Abstract][Full Text] [Related]
31. Multiple isoforms of CDC25 oppose ATM activity to maintain cell proliferation during vertebrate development.
Verduzco D; Dovey JS; Shukla AA; Kodym E; Skaug BA; Amatruda JF
Mol Cancer Res; 2012 Nov; 10(11):1451-61. PubMed ID: 22986406
[TBL] [Abstract][Full Text] [Related]
32. The DNA damage response kinases DNA-dependent protein kinase (DNA-PK) and ataxia telangiectasia mutated (ATM) Are stimulated by bulky adduct-containing DNA.
Kemp MG; Lindsey-Boltz LA; Sancar A
J Biol Chem; 2011 Jun; 286(22):19237-46. PubMed ID: 21487018
[TBL] [Abstract][Full Text] [Related]
33. Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells.
Agarwal C; Tyagi A; Agarwal R
Mol Cancer Ther; 2006 Dec; 5(12):3294-302. PubMed ID: 17172433
[TBL] [Abstract][Full Text] [Related]
34. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress.
Liu S; Opiyo SO; Manthey K; Glanzer JG; Ashley AK; Amerin C; Troksa K; Shrivastav M; Nickoloff JA; Oakley GG
Nucleic Acids Res; 2012 Nov; 40(21):10780-94. PubMed ID: 22977173
[TBL] [Abstract][Full Text] [Related]
35. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
36. Reconstitution of human claspin-mediated phosphorylation of Chk1 by the ATR (ataxia telangiectasia-mutated and rad3-related) checkpoint kinase.
Lindsey-Boltz LA; Serçin O; Choi JH; Sancar A
J Biol Chem; 2009 Nov; 284(48):33107-14. PubMed ID: 19828454
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
38. ATR and ATM regulate the timing of DNA replication origin firing.
Shechter D; Costanzo V; Gautier J
Nat Cell Biol; 2004 Jul; 6(7):648-55. PubMed ID: 15220931
[TBL] [Abstract][Full Text] [Related]
39. Cadmium-induced DNA damage triggers G(2)/M arrest via chk1/2 and cdc2 in p53-deficient kidney proximal tubule cells.
Bork U; Lee WK; Kuchler A; Dittmar T; Thévenod F
Am J Physiol Renal Physiol; 2010 Feb; 298(2):F255-65. PubMed ID: 19923412
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Tsvetkov L; Stern DF
Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
